LFCR FY2025 EPS Forecast Lifted by Barrington Research

Lifecore Biomedical, Inc. (NASDAQ:LFCR - Free Report) - Equities researchers at Barrington Research raised their FY2025 EPS estimates for shares of Lifecore Biomedical in a research note issued to investors on Wednesday, January 8th. Barrington Research analyst M. Petusky now forecasts that the company will earn ($0.98) per share for the year, up from their prior forecast of ($0.99). The consensus estimate for Lifecore Biomedical's current full-year earnings is ($0.99) per share. Barrington Research also issued estimates for Lifecore Biomedical's FY2026 earnings at ($0.60) EPS and FY2027 earnings at ($0.40) EPS.

Several other equities analysts have also recently commented on the stock. Stephens reissued an "equal weight" rating and set a $6.00 target price on shares of Lifecore Biomedical in a research note on Friday, January 3rd. Craig Hallum increased their price target on Lifecore Biomedical from $8.00 to $10.00 and gave the company a "buy" rating in a research note on Friday, November 22nd.

Lifecore Biomedical Stock Performance

Shares of NASDAQ:LFCR traded up $0.49 on Friday, hitting $6.29. The company's stock had a trading volume of 325,180 shares, compared to its average volume of 602,230. The company has a market capitalization of $231.64 million, a price-to-earnings ratio of 78.63 and a beta of 0.98. The company has a debt-to-equity ratio of 12.90, a quick ratio of 0.80 and a current ratio of 1.83. Lifecore Biomedical has a 12 month low of $3.68 and a 12 month high of $8.90. The stock's 50-day moving average is $7.05 and its two-hundred day moving average is $5.82.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last announced its quarterly earnings results on Thursday, January 2nd. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.02. Lifecore Biomedical had a net margin of 5.09% and a negative return on equity of 382.65%.

Institutional Trading of Lifecore Biomedical

Hedge funds have recently made changes to their positions in the stock. Marshall Wace LLP grew its position in Lifecore Biomedical by 87.3% in the second quarter. Marshall Wace LLP now owns 300,120 shares of the company's stock worth $1,540,000 after acquiring an additional 139,887 shares in the last quarter. 272 Capital LP boosted its holdings in Lifecore Biomedical by 511.1% in the third quarter. 272 Capital LP now owns 143,480 shares of the company's stock worth $707,000 after purchasing an additional 120,002 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in Lifecore Biomedical during the second quarter worth $327,000. Geode Capital Management LLC raised its holdings in Lifecore Biomedical by 10.3% during the third quarter. Geode Capital Management LLC now owns 597,685 shares of the company's stock valued at $2,948,000 after buying an additional 55,703 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its position in shares of Lifecore Biomedical by 2,640.5% in the third quarter. BNP Paribas Financial Markets now owns 54,399 shares of the company's stock worth $268,000 after buying an additional 52,414 shares during the last quarter. 83.36% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Lifecore Biomedical news, CEO Paul Josephs purchased 17,000 shares of the company's stock in a transaction that occurred on Wednesday, January 8th. The shares were purchased at an average cost of $5.74 per share, with a total value of $97,580.00. Following the completion of the transaction, the chief executive officer now owns 559,717 shares of the company's stock, valued at approximately $3,212,775.58. This represents a 3.13 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 28.21% of the stock is currently owned by company insiders.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.